From NASDAQ: 2024-04-10 18:15:20

Vanda Pharmaceuticals (VNDA) closed at $4.28, down 1.83% from the previous day, lagging behind the S&P 500, which fell by 0.95%. The stock has climbed 12.37% in the past month, outperforming the Medical sector and S&P 500. Analysts project a 16.67% decrease in upcoming EPS and a 22.4% drop in revenue.

The Zacks Rank system assigns Vanda Pharmaceuticals a #3 (Hold) rating. Recent changes in analyst estimates may indicate shifts in business trends. The Medical – Biomedical and Genetics industry, where Vanda belongs, ranks in the top 32% of all industries. Utilize Zacks.com for stock-moving metrics and industry updates.

Zacks Investment Research released a Special Report on Bitcoin, predicting significant upward potential. Bitcoin has historically yielded high returns in election years, such as +272.4% in 2012 and +302.8% in 2020. Zacks anticipates another surge and offers a free report on Bitcoin’s history and potential profitability. Download the report for insights and recommendations.



Read more at NASDAQ: Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know